Purpose A subretinal implant termed CPCB-RPE1 is currently being developed to surgically replace dystrophic RPE in patients with dry age-related macular degeneration (AMD) and severe vision loss. CPCB-RPE1 is composed of a terminally differentiated, polarized human embryonic stem cell-derived RPE (hESC-RPE) monolayer pre-grown on a biocompatible, mesh-supported submicron parylene C membrane. The objective of the present delivery study was to assess the feasibility and 1-month safety of CPCB-RPE1 implantation in Yucatán minipigs, whose eyes are similar to human eyes in size and gross retinal anatomy. Methods This was a prospective, partially blinded, randomized study in 14 normal-sighted female Yucatán minipigs (aged 2 months, weighing 24-35 kg). Surgeons were blinded to the randomization codes and postoperative and post-mortem assessments were performed in a blinded manner. Eleven minipigs received CPCB-RPE1 while three control minipigs underwent sham surgery that generated subretinal blebs. All animals except two sham controls received combined local (Ozurdex™ dexamethasone intravitreal implant) and systemic (tacrolimus) immunosuppression or local immunosuppression alone. Correct placement of the CPCB-RPE1 implant was assessed by in vivo optical coherence tomography and postmortem histology. hESC-RPE cells were identified using immunohistochemistry staining for TRA-1-85 (a human marker) and RPE65 (an RPE marker). As the study results of primary interest were nonnumerical no statistical analysis or tests were conducted. Results CPCB-RPE1 implants were reliably placed, without implant breakage, in the subretinal space of the minipig eye using surgical techniques similar to those that would be used in humans. Histologically, hESC-RPE cells were found to survive as an intact monolayer for 1 month based on immunohistochemistry staining for TRA-1-85 and RPE65. Conclusions Although inconclusive regarding the necessity or benefit of systemic or local immunosuppression, our study demonstrates the feasibility and safety of CPCB-RPE1 subretinal implantation in a comparable animal model and provides an encouraging starting point for human studies.
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Introduction
Age-related macular degeneration (AMD) is the leading cause of blindness among the elderly worldwide and is characterized by the degeneration of retinal pigment epithelium (RPE) and photoreceptor cells in the central region of the retina, leading to progressive and significant central vision loss [1] . In the era before the advent of vascular endothelial growth factortargeted treatment, surgical pioneers subretinally transplanted autologous adult [2] or allogeneic homologous fetal RPE in wet and dry human AMD but rejection rates were high despite better outcomes in dry AMD [3] . In recent years, research has focused on cell-based treatments for AMD, particularly on differentiating human embryonic stem cells (hESCs) into RPE (termed hESC-RPE) and replacing damaged RPE with hESC-RPE [4] . These hESC-RPE transplantation efforts primarily aim to restore the subretinal physiologic interactions between the RPE and photoreceptors [5, 6] .
The two methods primarily used for the subretinal transplantation of hESC-RPE are to inject an hESC-RPE cellular suspension or implant an hESC-RPE monolayer grown on a substrate. However, RPE cells form a polarized monolayer in vivo, between the underlying Bruch's membrane and overlying photoreceptors, and it is questionable whether a cellular suspension can produce the polarization required to restore vision [5] . Therefore, an implant termed CPCB-RPE1, which utilizes an hESC-RPE monolayer cultured on a meshsupported submicron parylene-C membrane (MSPM; mimicking the Bruch's membrane), has been developed under the auspices of the California Project to Cure Blindness (CPCB) [7, 8] . This implant has been designed to treat patients with dry AMD (dAMD) and severe vision loss by being surgically placed into the subretinal space, replacing the dystrophic RPE and providing physiological support for the overlying photoreceptors.
The present study in the Yucatán minipig was conducted to assess (1) the feasibility of subretinal delivery of CPCB-RPE1, (2) its 1-month safety and tolerability under local or combined local and systemic immunosuppression, and (3) the analysis of the implanted cells by immunohistochemistry approximately 1 month after surgery. This was the first study using CPCB-RPE1 to be conducted in a larger mammalian species whose eyes are similar to human eyes in size and gross retinal anatomy, allowing similar subretinal transplantation techniques to be assessed before human testing.
Materials and methods

Study device
The study device, termed CPCB-RPE1, consisted of a meshsupported submicron parylene-C membrane (MSPM) and hESC-RPE. The MSPM was vitronectin-coated, overall creating a biocompatible mesh specifically designed to support the culture and subretinal implantation of an hESC-RPE confluent monolayer [7, 9] . Serving as an artificial Bruch's membrane, the MSPM was 6.25 mm in length and 3.5 mm in width, with 0.4 μm (μm) ultra-thin membrane pore areas covering nearly 50 % of the total surface area (Fig. 1a, left) .
Before being seeded onto the MSPM, hESCs were cultured in defined conditions using serum-free medium (X-VIVO 10™, Lonza, Walkersville, MD, USA) and Matrigel, and spontaneously differentiated to hESC-RPE through the removal of soluble growth factors. After approximately 100 days, unpigmented cells were manually removed and remaining enriched hESC-RPE cells were passaged using TrypLE™ (Life Technologies, Inc, Bethesda, MD). Secondpassage hESC-RPE cells were cryopreserved as an intermediate cell bank. These cultures have been extensively characterized and are 99 % positive for RPE markers [10] .
Passage three cells were thawed and then seeded onto MSPM at a density of 10 5 cells/cm 2 and grown to confluence for approximately 4 weeks, achieving a final density of 10 5 cells/MSPM (Fig. 1a, right) . Before implantation, implants were checked for confluence, pigmentation, and cobblestone-like morphology of their hESC-RPE monolayers (Fig. 1b) . MSPMs that did not meet the quality control criteria were discarded. This process generated a polarized hESC-RPE monolayer with characteristics similar to human fetal RPE which would promote survival of the monolayer in vivo [8, 11] .
Animals
Normal-sighted, purpose-bred female Yucatán minipigs (S&S Farms Inc., USA) were used in this study. Animals were housed and fed in facilities approved by the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC). All study procedures were performed in accordance with the Institutional Animal Care and Use Committee (IACUC) of the University of Southern California (USC).
Animals underwent a baseline and postoperative physical examination (USC Department of Animal Services Veterinarian) and a blinded baseline and postoperative ocular examination by an independent veterinary ophthalmologist. If the veterinarian was unavailable, fundus photographs of the eyes were taken before and after surgical procedures. Animals were anesthetized using weight-based dosing of intramuscular Telazol® (100 mg/ml; Zoetis Inc., Kalamazoo, MI, USA) for baseline examinations and placement of a vascular access port (VAP).
Animals were euthanized by trained staff of the USC Department of Animal Services using a lethal overdose of Euthasol® (Virbac Corp., Fort Worth, TX, USA). Euthanasia was confirmed by clinical assessment of respiration and cardiac function as well as pulse oximetry.
Study design
This was a prospective, partially blinded study in 14 twomonth-old, normal-sighted, female Yucatán minipigs, weighing 24-35 kg, to assess the feasibility of subretinal implantation of CPCB-RPE1 and implant safety and tolerability over a 1-month observation period following the surgery. Surgeons were blinded to the randomization codes and postoperative and post-mortem assessments were performed in a blinded manner. The study was conducted at the Department of Ophthalmology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA from 01-July-2013 to 24-December-2014.
The 14 animals were randomized to one of three study groups. Group 1 consisted of eight animals that underwent surgical implantation of CPCB-RPE1 in the subretinal space and were maintained on both systemic (tacrolimus) and local (Ozurdex™ dexamethasone intravitreal implant; Allergan Inc., Irvine, CA) immunosuppression. Systemic immunosuppression was administered via a VAP surgically placed in the right external jugular vein. Group 2 consisted of three animals that underwent CPCB-RPE1 implantation and local immunosuppression (Ozurdex™) alone. Group 3 consisted of three animals that underwent sham surgery consisting of subretinal bleb creation instead of CPCB-RPE1 implantation and received no immunosuppressant (two animals) or local immunosuppression (one animal). All animals were maintained for ≥30 days unless a change in health status, such as systemic sepsis, warranted euthanasia earlier. All animals were maintained in the group to which they were originally assigned, even if systemic immunosuppression was interrupted or terminated early due to limitations in vascular access or systemic illness.
Optical imaging
Baseline imaging included optical coherence tomography (OCT; Heidelberg Spectralis™, Heidelberg Engineering, Heidelberg, Germany), fluorescein angiograms, and fundus photographs (RetCam™, Clarity Medical Systems Inc., Pleasanton, CA, USA) to document retinal state if an independent clinical examiner was not available. Imaging procedures were similarly repeated at euthanasia for comparative analysis with baseline images unless retinal viewing was obstructed (e.g., due to cataract). Postoperative follow-up imaging was performed unless posterior pole viewing was obscured by corneal, lenticular, or vitreous opacity.
Surgical procedures and postoperative care
Before surgery, anesthesia was induced with intramuscular Telazol® (100 mg/ml; Zoetis Inc., Kalamazoo, MI, USA) and maintained with sevoflurane gas under veterinary supervision. The operative site was prepped and draped with a sterile field after scrubbing with 10 % povidone iodine. Standard vitreoretinal surgical methods and equipment (Stellaris™ PC posterior vitrectomy system, Bausch & Lomb, Rochester, NY, USA) were employed to deliver CPCB-RPE1 to the left eyes of Yucatán minipigs, using the same surgical delivery tool that would be employed in human surgeries. Fine forceps and Wescott scissors were then used to perform a 360°peritomy. A 20-gauge sclerotomy was then made using a micro-vitreoretinal blade at the preplaced suture site and a 20-gauge infusion line placed and secured there. Two additional sclerotomy sites were similarly made at the surgeon's discretion to facilitate ideal retinal access for placement of CPCB-RPE1. Photon light fibers were placed to Zeiss Meditec Inc., Dublin, CA, USA) with a binocular indirect ophthalmomicroscope (BIOM; OCULUS Surgical Inc., Port St. Lucie, FL, USA) was used to visualize the intraocular environment. A dissecting microscope and sterile technique were used for preparation of CPCB-RPE1 for intraocular injection as described below.
Intraocular injection of Triesence® (Alcon Laboratories Inc., Fort Worth, TX, USA) was used to help with visualization of the vitreous and vitrectomy (i.e., removal of the vitreous humor) in most cases. At the surgeon's discretion, an area of the retina was selected for the site of retinotomy. Then, a 41-gauge a soft tip cannula mounted on a silicone oil injector was used to access the subretinal space and create a subretinal bleb using an infusion of balanced salt solution (BSS). Before the retinotomy, this site was lasered or diathermized lightly to minimize potential bleeding. During the retinotomy the intraocular pressure was elevated to 60 mmHg to prevent any bleeding. Next, one of the sclerotomies was enlarged by 1-2 mm using a microvitreoretinal blade to allow insertion of a custom-made delivery tool. Animals that were in the sham group only underwent this portion of the procedure and none of the subsequent steps except for closure of the wounds.
During the vitrectomy, and at the surgeon's discretion, the CPCB-RPE1 was retrieved from a standard cell culture incubator (in the same building as the surgical suite) by an assistant and then removed from the culture medium with sterile forceps using the implant's accessory tab (which was designed for this purpose). The surgeon then sterilely cut off the accessory tab under a dissecting microscope and loaded the implant into the custom-made delivery tool (Synergetics Inc., O'Fallon, MO, USA). The tool's tip remained submerged in BSS for 8 to 13 min, at which point the surgeon implanted the CPCB-RPE1 in the subretinal space. To deliver CPCB-RPE1, the pre-loaded delivery tool described above was inserted into the eye and the tip carefully placed into the subretinal space through the above-described retinotomy. Once the tool's tip was properly localized, CPCB-RPE1 was delivered into the subretinal space and the delivery tool removed. Nearly simultaneously, the eye was instilled with perfluorocarbon liquid to flatten the bleb and prevent the implant from extruding through the retinotomy. The perfluorocarbon was removed with a soft tip cannula and replaced with air. The retina was inspected for bleeding or signs of retinal detachment and attempts were made to treat any such problems. Finally, a silicone oil injector was used to replace the air with 1000 or 5000 centistoke silicone oil. The infusion line was removed and the sclerotomies and overlying conjunctiva closed using 6-0 vicryl suture.
Postoperative examinations were performed on postoperative day 1, week 1 and then weekly thereafter unless any complications or problems were noted. All animals were monitored by veterinary staff for normal behaviors, including feeding, drinking, urination, and stools. Animals received buprenorphine for postoperative pain management as well as topical Maxitrol® ointment (Alcon Laboratories Inc., Fort Worth, TX, USA) for infection and inflammation prophylaxis during the first postoperative week, as needed.
Histology and immunohistochemistry
After sacrifice, surgically treated eyes were enucleated using standard, globe-preserving surgical techniques and prepared for histologic examination of the implantation site. All harvested eyes were fixed in Davidson's solution, preserved in formalin, and then cut in half to remove the posterior half but retain the quadrant containing the implant or subretinal bleb. The retained region was embedded in paraffin and serially sectioned into 5-μm-thick slices using a microtome.
Hematoxylin-eosin (HE) staining was performed on every 10th slide of all serially sectioned eye tissues to histologically visualize cells on the implant. HE-stained slides were scanned using the Aperio Scanscope CS microscope hardware and software (Aperio Technologies Inc., Vista, CA, USA). After scanning, images of each slide were taken at 2×, 4×, and 10× magnification to archive and analyze the images. To check for the safety of the surgery, the placement of the CPCB-RPE1 was evaluated in a masked manner and determined as the percentage of the implant in the subretinal space.
Immunohistochemistry staining for TRA-1-85 and RPE65 (a human marker and an RPE marker, respectively) was performed to identify hESC-RPE cells. One slide from each sample was stained. Slides were deparaffinized and rehydrated before staining. Slides were incubated with the following primary antibodies overnight at 4°C: monoclonal mouse anti-TRA-1-85 (R&D Systems Inc., Minneapolis, MN, USA; MAB3195; 1:100) and polyclonal rabbit anti-RPE65 (Abcam plc, Cambridge, UK; Ab105366; 1:500). Slides were incubated with the appropriate rhodamine or FITC-conjugated secondary antibodies (Jackson ImmunoResearch Laboratories Inc., West Grove, PA, USA; 117098 and 113127; both 1:100) for 1 h at room temperature and then mounted with fluorescent-enhance mounting medium containing 4',6-diamidino-2-phenylindole (DAPI; Vector Laboratory Inc., Burlingame, CA, USA). Images were acquired using an Ultraviewer ERS dual spinning disk confocal microscope (PerkinElmer, Waltham, MA, USA) equipped with a CApochromat 10× high dry lens, a C-Apochromat 40× water immersion lens NA 1.2 and an electron multiplier CCD cooled digital camera. All slides were scanned under the same conditions for magnification, brightness, and gain. Images were captured and processed using Volocity® 3D Image Analysis Software (PerkinElmer). Scoring of immunostained slides was standardized. TRA-1-85/RPE65 scoring was set at four levels: negative (−), weakly positive (+), moderately positive (++), and strongly positive (+++). The scoring criteria for TRA-1-85/RPE65 combined previous staining experience and comparison of several stained slides from this study.
Data collection and analysis
The data of primary interest in this study were nonnumerical. No statistical analysis or tests were conducted.
Results
Clinical findings
Baseline examination of the eyes in all minipigs revealed no major abnormalities, except for occasional microscopic hemorrhage in the retinal periphery in one animal. Upon baseline examination, intraocular pressures were also within normal limits (10-20 mmHg). Postoperatively, minipigs were maintained for a median (range) observation period of 31 (13-43) days. Table 1 summarizes the animals' clinical characteristics.
All animals that received CPCB-RPE1 underwent the subretinal implantation successfully; expected postoperative observations (mild bleeding in the vitreous/oil space in two animals; elevated intraocular pressure up to 24 mmHg in one animal) within 2 days after surgery were transient and did not result in rejection of the implant. Comprehensive postoperative clinical examination of the operated eye demonstrated expected, but clinically insignificant, postoperative changes associated with vitrectomy, e.g., mild conjunctival congestion, conjunctival hyposphagma, mild cataract, and subconjunctival hemorrhage in all animals. These changes generally resolved within 1-2 weeks of surgery. One animal that received CPCB-RPE1 developed a focal peripheral retinal detachment during surgery that was successfully treated intraoperatively by means of fluid-air exchange, drainage of subretinal fluid, and peripheral laser coagulation. There were no other sequelae or consequences for the CPCB-RPE1, which was implanted at the central retina. Intraocular pressures did not change markedly in the postoperative period and remained below 20 mmHg. All vitrectomy wounds healed normally and without complications in all animals.
Implant placement and retinal findings
Postoperative clinical examination of the posterior segment of the retina in vivo demonstrated subretinal location of all CPCB-RPE1 in all animals except one, in which <50 % of the implant was located subretinally, the remainder of the implant, especially its handle, being located intraretinally. Fundus imaging demonstrated good subretinal placement without any gross defects, bends or folds in 6/8 (75 %) minipigs in group 1. No breaks were observed in the implanted CPCB-RPE1 membranes. Mild bends in the handle As expected, in all cases where the handle of the CPCB-RPE1 implant was adjacent to or underneath the retinotomy site, there was thinning of the overlying retina on OCT images, as shown in Fig. 2 . This was consistent with the appearance of chorioretinal scarring on the retina in this area, which was due to the thermal damage caused by laser and diathermy treatments during surgery. In addition, retinal thinning was also present in control animals that had undergone laser or diathermy but no CPCB-RPE1 implantation, confirming that the overlying retinal thinning was due not to the implant but to the laser treatment at the retinotomy site, which is expected. In no case was there a retinal detachment, hemorrhage or protrusion of the handle through the retina. In cases where the handle of the CPCB-RPE1 implant was positioned further away from the retinotomy site (7/11 pigs), there was no thinning of the overlying retina, suggesting that the handle by itself did not have an adverse effect on the overlying retina (Fig. 3) .
Vascular access port-related observations
All eight group 1 animals and one group 3 control in our 1-month study were assigned to receive VAPs for systemic immunosuppression (Table 1) . Of these nine animals, four (44 %; three from group 1 and the systemically immunosuppressed control) were euthanized early due to sepsis between 1 and 3 weeks after VAP placement, and two others (22 %) from group 1 dislodged their VAPs at least once, resulting in an incomplete course of immunosuppression. Therefore, only 3/9 (33 %) animals undergoing systemic immunosuppression (pigs A, C, and M) completed the 1-month study as planned. Two of the four animals that were euthanized early showed signs of endogenous endophthalmitis and infectious chorioretinitis secondary to ocular seeding of bacteria. One of these animals had a serous retinal detachment but no rhegmatogenous retinal detachment. None of these findings were associated with the surgical procedure or the implant itself. The study data are summarized in Table 1 .
Histology and immunohistochemistry
Histological analysis was available on 10/11 animals receiving CPCB-RPE1 (groups 1 and 2) and 2/3 sham-operated (group 3) animals. As shown in Table 2 , nine of the ten eyes (90 %) with the implant exhibited satisfactory implant placement; seven of these satisfactorily placed implants (77.8 %) had 100 % of the implant located in the subretinal space. Only 1/10 (10 %) of the implanted eyes (from group 1) had <50 % of the implant located subretinally (with the majority of the implant located intraretinally). As regards sham surgery, which involved the creation and immediate intraoperative draining of a subretinal bleb, histology revealed some scarring of the outer retina but no defect of the adjacent retina.
In the seven animals that had CPCB-RPE1 positioned entirely in the subretinal space, the retinal structure remained largely intact with only minimal changes, such as focal disruption and slight inner nuclear layer (INL) thinning. Normal INL structure and thickness was observed in 6/10 (60 %) of eyes, focal disruption due to the implant but retention of normal INL thickness was observed in 1/10 (10 %) of eyes, and focal disruption accompanied by focally thinned INL overlying the implant was observed in 2/10 (20 %) of eyes. Most samples (8/10, 80 %) showed some thinning of the outer nuclear layer (ONL) overlying the CPCB-RPE1. Although the neural retina and RPE were artifactually separated as a result of tissue processing, the properly oriented inner and outer segments of photoreceptors and a lack of a debris zone suggested that interdigitation between host photoreceptor outer segments and apical sides of the implanted human RPE in the CPCB-RPE1 was present in most eyes (9/10). Only one eye, which had extensive intraretinal instead of the anatomically correct subretinal placement, showed significant damage to the retinal structure, including atrophy and fibrosis. All examined implanted eyes (10/10; 100 %) displayed normal host RPE and choroid morphology.
No local inflammatory response was observed in any of the eyes. In 3/10 (30 %) of eyes, focal, mild fibrosis was observed; two of these eyes had focal fibrosis at the basal side of the CPCB-RPE1, and the remaining one eye had a small focal area of fibrosis in the choroid. None of the eyes had periimplant fibrosis. Histological analysis of hESC-RPE on CPCB-RPE1 after implantation revealed that all eyes (10/10; 100 %) had a single layer of pigmented and cobblestone-shaped cells regularly aligned on the implant, as visualized using hematoxylineosin (HE) staining (Fig. 4) . Immunohistochemical staining demonstrated that the CPCB-RPE1 cells were positive for the human and RPE markers TRA-1-85 and RPE65, indicating that the hESC-RPE cells in those samples had survived 1 month of implantation (Fig. 4 and Table 1 ). The host RPE cells were strongly positive for RPE65.
Histological analysis of the region surrounding the implant handle revealed expected focal cell loss, when it was adjacent to the retinotomy site. The CPCB-RPE1 implant handle was designed and manufactured for manipulation of the CPCB-RPE1 during the process of loading it into the surgical injector tool, so possible focal cell damage and focal denting, as well as bending of the handle itself, were anticipated. The handle of the CPCB-RPE1 implant was identified histologically (Fig. 5 ) based on width (1-1.5 mm for the handle and 3.5 mm for the body) and by the absence of ultrathin areas, which are only found on the body of the MSPM. In the five pig eyes with definitively identifiable handles, one handle (1/5; 20 %) demonstrated focal denting and bending (see pig B in Fig. 5 ), while all five (100 %) handles showed focal cell loss and partial intraretinal implantation with associated pathology. Intraretinal location was most common at the distal end of the handle, i.e., the area furthest from the body. Sections of the handle taken closer to the implant's body were flat and entirely positioned within the subretinal space. To avoid implant intraretinal location, complete subretinal placement should be achieved in future applications.
Discussion
The present study in 14 Yucatán minipigs is the first investigation of surgical subretinal delivery of the CPCB-RPE1 implant, an hESC-derived RPE monolayer on an MSPS carrier, in a mammalian species whose eye is similar to the human eye in size and gross retinal anatomy, allowing similar subretinal transplantation techniques to be assessed before human testing. The advantages of the surgically foldable MSPS carrier include customized macular shape in diameter and thickness [8] , ultrathin parts with diffusion [7] , and excellent RPE adherence [10, 11] and survival [12] , whereas its nondegradability and unknown long-term effects can be seen as disadvantages. The study criteria for successful implantation were appropriate placement of the implant in the subretinal space, as assessed by OCT and post-mortem histology. The study demonstrated that the CPCB-RPE1 can be reliably implanted into the subretinal space of the swine eye using surgical techniques similar to those that would be used in humans. Thorough in vivo examinations demonstrated safe placement Areas indicated by rectangles in a and b are magnified on the right. Implanted hESC-RPE overlying the mesh-supported submicron parylene membrane (MSPM) with alternating ultrathin and thick areas (arrows, black and white) and host RPE (white stars) is indicated. INL inner nuclear membrane; ONL outer nuclear membrane of the implant without severe clinical complications, e.g., postoperative endophthalmitis, intraocular hypotension or hypertension, or retinal detachment. Moreover, while surgical implantation of CPCB-RPE1 into a normal eye was expected to result in some damage to the overlying retina, retinal basic structure remained intact with only minimal changes when the implant was placed entirely in the subretinal space. No breakage of the CPCB-RPE1 was observed. Histology demonstrated that the RPE cells in the CPCB-RPE1 survived as an intact monolayer after implantation. There was also no evidence of a local inflammatory response or peri-implant fibrosis in any of the eyes. In line with an earlier study we conducted in rats [12] , no formation of teratoma or ectopic tissue was observed in the minipig eye. Immunohistochemistry for TRA-1-85 and RPE65 was positive in all of the CPCB-RPE1 implants, indicating that the hESC-RPE cells survived in those samples after 1 month of implantation. Of note, RPE65 was also labeled in the outer segments of a subset of host photoreceptors, which is consistent with a report that RPE65 is found in outer segments of a subset of cones (green/red) [13] . However, the necessity or benefit of systemic tacrolimus or local dexamethasone immunosuppression for this procedure remains unclear due to the variability of maintaining swine on systemic immunosuppression. The safety and tolerability issues encountered in this study were related to VAP dislodgement, VAP site infection, and the resulting sepsis in the systemically immunosuppressed animals rather than to the implant or the surgical procedure as such. In several cases there were interruptions in the immunosuppression regimen from either unanticipated removal of VAPs by the animals themselves or surgical removal of the ports due to surgical site infections. Therefore, the role of immunosuppression in the survival of this implant is unclear. However, the fact that there were interruptions of immunosuppression and the lack of any focal inflammatory response around the CPCB-RPE1 implant suggest that systemic immunosuppression may not be necessary for survival of CPCB-RPE1 in the subretinal space in minipigs.
Cell-based subretinal implantation using carrier substrates is surgically feasible. RPE transplantation in the pig is a relatively young field, and surgical implications of such implantations have not been fully explored [14] [15] [16] [17] [18] [19] [20] [21] . Human autologous RPE transplantation studies, primarily in patients with exudative AMD, have shown that intraoperative complications are infrequent [22] [23] [24] . No such complications were observed in our study. Early and late postoperative complications in human subjects, however, have included intraocular hemorrhage, serous macular detachment, epiretinal membrane formation, the development of proliferative vitreoretinopathy, or the induction of choroidal neovascularization in a patient who previously had dAMD [23, 25] .
In the present study, our surgical technique did not cause any retinal or choroidal bleeding, a potential complication reported to occur in eight of 11 pigs after autologous RPE-choroid graft transplantation [20] . We created a subretinal bleb before the insertion of our transplant. The effects of bleb creation have been investigated, mostly in rabbits [26] . Our study primarily aimed to investigate the surgical safety of hESC-RPE transplantation with regard to, e.g., retinal detachment or proliferative vitreo-retinopathy. However, it may be considered a potential limitation of our study that we did not prospectively examine retinal response using multifocal electroretinography (mfERG). Christiansen et al. elaborated this sensitive technique and were able to provide reliable data on the electrophysiologic dependencies of different subretinal materials [18, 27] . Although we had no robust mfERG setup in place and would endorse including mfERG in future studies, we feel confident regarding the biocompatibility of the material with and without cells due to our experience with the optokinetic nystagmus and superior colliculus recordings in the RCS rat (data submitted to FDA with an Investigational New Drug submission; this aspect is also discussed in a recent review article by our group [28] ). We observed normal INL structure and thickness in most (60 %) eyes, focal implant-related disruption in some (30 %) cases and some ONL thinning in the implantation area in the majority (80 %) of eyes. Despite some tissue processing-related artifacts, histology suggested that interdigitation between host photoreceptor outer segments and apical sides of the implanted human RPE was present in almost all (90 %) eyes.
In humans, it is widely accepted that the RPE is anchorage dependent; RPE cells must attach to an adequate Bruch's membrane-like substrate to avoid cell death [29, 30] . Del Priore and coworkers observed allogeneic RPE graft survival in non-immunosuppressed pigs for up to 3 months without surgical RPE debridement, but this was associated with marked shortening of the outer segments and a multilayer of heavily pigmented RPE [14] . Others performed a surgical RPE debridement before RPE transplantation and observed RPE proliferation and decreased photoreceptor loss [16, 31] . In our setup, which was without a debridement because we primarily investigated the surgical safety of hESC-RPE transplantation, we did not encounter any Tcell mediated immunohistologic reaction from the host RPE or any fluid accumulation around the transplant, such as macular edema. In AMD the decline in hydraulic conductance of Bruch's membrane is very important; it may lead to RPE detachment and lipid accumulation [32, 33] . One future experimental setup for our technique would be to incorporate RPE debridement to address various pitfalls, e.g., retinal bleb creation in atrophic regions, in human subretinal AMD surgery. Any subretinal transplantation, with or without synthetic implants, must have adequate hydraulic conductance to prevent pooling of fluid at the RPE substrate interface [34] . In our non-aged pigs, fluorescein angiography demonstrated no fluid pooling, neovascularization, or insufficient perfusion of the retina or choroid associated with implantation. Patent physiologic vascularization supports our previous MSPM biocompatibility testing and the impression from the RCS rat surgeries, where none of these issues linked to decreased conductance were observed [7, 8] .
Unlike Warfvinge et al. [21] , who observed large choroidal infiltrates 2-5 weeks after subretinal transplantation of murine retinal progenitor cells derived from non-immunosuppressed mice, we found that all studied eyes with immunosuppression presented a normal choroid. Del Priore observed no significant inflammatory response after non-immunosuppressed allogeneic porcine RPE sheet transplantation [14] . In pilot studies, in which we performed larger retinotomies using larger transplantation tools and had up to 14 weeks' follow-up with no immunosuppression, we encountered severe choroidal inflammatory reactions after surgery [35] . Our decision to employ immunosuppression is also in accordance with the only human hESC-RPE trial, which used low-dose tacrolimus and mycophenolate mofetil to prevent RPE rejection, but we primarily advocate minimalistic surgery, as applied here, so as not to unduly compromise the subretinal space [4] . Using combined systemic tacrolimus and local dexamethasone or local dexamethasone alone for immunosuppression in the present study, we obtained greatly improved in vivo imaging and ex vivo histological results compared to no immunosuppression, even if systemic immunosuppression was frequently incomplete due to VAP dislodgement. Our immunostaining demonstrated an absence of inflammatory cells, indicating an absence of host reaction to the CPCB-RPE1.
Several strengths and limitations warrant discussion. Animals were randomized to CPCB-RPE1 implantation or sham surgery and surgeons were blinded to randomization codes and to whether or not animals were to receive systemic tacrolimus. However, the study was of a limited size and its design did not require balanced groups. In addition, VAP dislodgement resulted in incomplete systemic immunosuppression, thus obscuring the role of immunosuppression for hESC-RPE survival. Moreover, we cannot preclude that the sepsis warranting early euthanasia in the 3/8 animals receiving both the CPCB-RPE1 and combined systemic and local immunosuppression was related to the immunosuppressants. To clarify the importance of immunosuppression the study design would need to incorporate appropriate controls and, most likely, a follow-up period of more than 30 days. Another limitation was a lack of fundus autofluorescence (FAF) imaging, which would have yielded an in vivo understanding of the transplanted hESC-RPE. The study was also limited by the time frame; testing over a longer follow-up period would have been more informative. We experimented with using multifocal electroretinography, different from the type used by Kyhn et al. in a pilot surgery [18] , but encountered too much noise to obtain reliable in vivo data. Overall, we believe that a sustained and successful RPE transplantation mandates the safe transplantation of a polarized monolayer to physiologically achieve or maintain visual acuity and avoid cell death over time. Finally, there are certain differences between the swine and human eye that limit which surgical methods can successfully be used in this animal compared to in humans [36] . Nonetheless, the minipig eye can be considered sufficiently similar to the human eye to serve as an in vivo model for retinal surgery studies.
Conclusions
Our study shows it is feasible to successfully and reliably deliver the CPCB-RPE1 into the subretinal space of the Yucatán minipig eye using a custom-made surgical delivery tool along with tools and methods commonly used in human vitreoretinal surgery. In the vast majority of cases (91 %), clinical examination, imaging and histological analysis showed that the CPCB-RPE1 implant remained in the subretinal space for the duration of implantation, even if 10-20 % of the implant had intraretinal localization histologically. Furthermore, overall retinal preservation was demonstrated via in vivo imaging and histology of the ONL and photoreceptor outer segment overlying the implant. Minimal retinal changes observed could be easily attributed to diathermy and laser photocoagulation that was used as a standard part of the surgery. There was no evidence of adverse events, retinal detachment, or focal inflammation associated with the body of the implant. Notably, there was no instance of retinal detachment despite histological evidence of focal denting and bending of the implant handle at the site of manipulation by the custom surgical tool. Moreover, there was no breakage of the CPCB-RPE1 implant in any case. In conclusion, although our study was inconclusive regarding the necessity or benefit of systemic or local immunosuppression, it demonstrated the feasibility and safety of CPCB-RPE1 subretinal implantation in an animal model comparable to the human eye. We are confident that our study provides an encouraging starting point for early human studies.
